NCT02505152

Brief Summary

To evaluate the values of percutaneous transhepatic intrahepatic portosystemic shunt for treatment of portal vein occlusion with symptomatic portal hypertension after splenectomy.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
4.8 years until next milestone

First Submitted

Initial submission to the registry

July 16, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 22, 2015

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Last Updated

November 11, 2015

Status Verified

November 1, 2015

Enrollment Period

6.2 years

First QC Date

July 16, 2015

Last Update Submit

November 10, 2015

Conditions

Keywords

Hypertension, PortalPortal Vein, Cavernous Transformation OfPortosystemic shuntRadiology, Interventional

Outcome Measures

Primary Outcomes (2)

  • No gastrointestinal rebleeding in 1 month after interventions

    No gastrointestinal rebleeding in 1 month after interventions

    1 month

  • Ascites disappear in 1 month after interventions

    Ascites disappear in 1 month after interventions

    1 month

Secondary Outcomes (1)

  • Whether the shunt is patent after interventions in 6 months

    6 months

Study Arms (1)

Shunt

EXPERIMENTAL

Perform percutaneous transhepatic intrahepatic portosystemic shunt

Procedure: Percutaneous transhepatic intrahepatic portosystemic shunt

Interventions

Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.

Shunt

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All patients with portal hypertension who have the history of splenectomy and have enough image information to confirm occlusion of portal vein

You may not qualify if:

  • Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Radiology

Guangzhou, Guangdong, 510000, China

RECRUITING

MeSH Terms

Conditions

Hypertension, PortalPortal Vein, Cavernous Transformation Of

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System Diseases

Study Officials

  • Zaibo Jiang, MD.

    Sun Yat-sen University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University

Study Record Dates

First Submitted

July 16, 2015

First Posted

July 22, 2015

Study Start

October 1, 2010

Primary Completion

December 1, 2016

Last Updated

November 11, 2015

Record last verified: 2015-11

Locations